Begin typing your search above and press return to search.
Going beyond birthday celebration
access_time 18 Sep 2020 6:05 AM GMT
Periyar@142-Revolutionary and Visionary
access_time 17 Sep 2020 11:57 AM GMT
The word of caution from the highest court
access_time 17 Sep 2020 6:31 AM GMT
access_time 16 Sep 2020 5:58 AM GMT
access_time 15 Sep 2020 6:19 AM GMT
DEEP READAll arrow_drop_down
The ogres in the mind
access_time 8 Sep 2020 11:27 AM GMT
Why worry about populism?
access_time 4 Sep 2020 9:51 AM GMT
Media mind-set towards minorities
access_time 15 July 2020 4:29 PM GMT
Homechevron_rightBusinesschevron_rightSun Pharma stocks...

Sun Pharma stocks plunge on revelation of whistleblower's complaint

Sun Pharma stocks plunge on revelation of whistleblowers complaint

Mumbai: The stock of pharmaceutical major Sun Pharma ended up as the top loser on the BSE Sensex on Friday following reports of a complaint by a whistleblower to the Securities and Exchange Board of India (Sebi) against the company.

The company scrip tanked over 12 per cent at one point to Rs 390.50 apiece, losing Rs 36.65, or 8.58 per cent, from its previous close of Rs 427.15.

After the steep fall in its share price, Sun Pharma in a letter to Sebi said there is great asymmetry in information circulating between analysts, investors and the media, leading to intense speculation.

"We wish to bring to your kind notice an alleged second whistleblower complaint filed against our Company, which we learnt from a media report on January 15, 2019," Sun Pharma said.

"There is a great asymmetry in the information circulating between analysts,

investors and media leading to intense speculation. The availability of information contained in the whistleblower documents to a set of selective investors does put other investors including retail investors in a disadvantageous position," it said.

"We are concerned that certain entities/individuals are adopting unfair trade practices prejudicial to the interest of shareholders and other stakeholders.

"It is evident from the fact that shareholders value has been drastically eroded within a short span of time due to unsubstantiated complaint/allegation against the company and mala fide campaign launched by certain media houses," it added.

The whistleblower's complaint regarding transactions that took place between 2014-2017 and were worth over Rs 5,800 crore, alleges that Indian drugs manufacturer Aditya Medisales Ltd had transactions with Suraksha Realty, controlled by Sun Pharma's co-promoter, Sudhir Valia.

Show Full Article
Next Story